Clinical trials
Observational Liver Cirrhosis, Biliary trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 17 |
| Completed | 17 |
| Unknown status | 7 |
| Active, not recruiting | 6 |
| Not yet recruiting | 2 |
| Terminated | 2 |
| Suspended | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Aarhus | 4 |
| Ipsen | 3 |
| Mayo Clinic | 3 |
| University Health Network, Toronto | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Fondazione Epatocentro Ticino | 2 |
| Intercept Pharmaceuticals | 2 |
| Perspectum | 2 |
| RenJi Hospital | 2 |
| Al-Azhar University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Liver Cirrhosis, Biliary | 54 |
| Cholangitis, Sclerosing | 13 |
| Hepatitis, Autoimmune | 9 |
| Liver Diseases | 5 |
| Non-alcoholic Fatty Liver Disease | 5 |
| Fibrosis | 4 |
| Liver Cirrhosis | 4 |
| Cholangitis | 3 |
| Cholestasis | 3 |
| Hepatitis | 3 |
Trials
Showing 26 to 50 of 54. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.